Treatment of Gram-Negative Bacillary Meningitis: Role of the New Cephalosporin Antibiotics

Results of the treatment of gram-negative bacillary meningitis have been disappointing: mortality is extremely high, and treatment with chloramphenicol has shown a high failure rate. This failure rate for chloramphenicol is consistent with the wide gap between minimal inhibitory concentration and mi...

Full description

Saved in:
Bibliographic Details
Published in:Reviews of infectious diseases 1982-09, Vol.4, p.S453-S464
Main Authors: Charles E. Cherubin, Corrado, Michael L., S. Ramachandran Nair, Myles E. Gombert, Sheldon Landesman, Guy Humbert
Format: Article
Language:English
Subjects:
Adult
Aminoglycosides - therapeutic use
Animals
Anti-Bacterial Agents - therapeutic use
Antibiotics
Bacterial Infections - drug therapy
Cefotaxime - metabolism
Cefotaxime - therapeutic use
Cephalosporins
Cephalosporins - therapeutic use
Chloramphenicol - therapeutic use
Clinical Trials as Topic
Dogs
Enterobacteriaceae Infections - drug therapy
Escherichia coli meningitis
Haemophilus meningitis
Humans
Infant
Infant, Newborn
Infections
Klebsiella
Listeria meningitis
Meningitis - drug therapy
Meningococcal meningitis
Pathogens
Pneumococcal meningitis
Session II: Clinical Studies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Results of the treatment of gram-negative bacillary meningitis have been disappointing: mortality is extremely high, and treatment with chloramphenicol has shown a high failure rate. This failure rate for chloramphenicol is consistent with the wide gap between minimal inhibitory concentration and minimal bactericidal concentration of this drug for Escherichia coli, Klebsiella, and other Enterobacteriaceae. Cefotaxime, a new cephalosporin, is cidal for most gram-negative bacteria at concentrations of
ISSN:0162-0886